Antienterococcal antibiotics

Medical Clinics of North America

Volumn 84, Issue 6, 2000, Pages 1471-1495

  Lefort, Agnes ^a   Mainardi, Jean Luc ^b   Tod, Michel ^c   Lortholary, Olivier ^c  

^a BEAUJON HOSPITAL   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c AVICENNE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN; AMPICILLIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM; CARBENICILLIN; CLAVULANIC ACID; COTRIMOXAZOLE; DALFOPRISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; DIBEKACIN; GLYCOPEPTIDE; ISEPAMICIN; KANAMYCIN; LINEZOLID; MACROLIDE; MEZLOCILLIN; MIKAMYCIN B; NETILMICIN; ORITAVANCIN; PENICILLIN BINDING PROTEIN; PENICILLIN G; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SISOMICIN; TETRACYCLINE; TICARCILLIN; TOBRAMYCIN; UNINDEXED DRUG;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; CLINICAL TRIAL; DRUG EFFICACY; DRUG POTENTIATION; ENTEROCOCCUS; HUMAN; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

EID: 0033660433     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(05)70298-4     Document Type: Article

References (166)

1. Effectiveness of ampicillin plus ceftriaxone or cefotaxime in the treatment of high-level aminoglycoside-resistant (HLAR) Enterococcus faecalis infective endocarditis
2. Replacement of the essential penicillin-binding protein 5 by high-molecular mass PBPs may explain vancomycin-β-lactam synergy in low-level vancomycin-resistant Enterococcus faecium D366
3. Modification of penicillin-binding proteins of penicillin-resistant mutants of different species of enterococci
4. Quinolones
5. Characterization and modelling of VanT: A novel, membrane-bound, serine racemase from vancomycin-resistant Enterococcus gallinarum BM4174
6. Moderate-level resistance to glycopeptide LY333328 mediated by genes of the vanA and vanB clusters in enterococci
7. Glycopeptide resistance in enterococci
8. Selection of glycopeptide-resistant mutants of VanB-type Enterococcus faecalis BM4281 in vitro and in experimental endocarditis
9. Lack of in vivo and in vitro bactericidal activity of N-formidoyl thienamycin against enterococci
10. The structure and mode of action of glycopeptide antibiotics of the vancomycin group
11. High-level aminoglycoside resistance among enterococci isolated from blood cultures
12. Evidence for an animal origin of vancomycin-resistant enterococci
13. Comparison of the antibacterial activities of the quinolones Bay 12-8039, gatifloxacin (AM 1155), trovafloxacin, clinafloxacin, levofloxacin and ciprofloxacin
14. Association constants for the binding of vancomycin and teicoplanin to N-acetyl-D-alanyl-D-alanine and N-acetyl-D-alanyl-D-serine
15. Modification of peptidoglycan precursors is a common feature of the low-level vancomycin-resistant vanB-type Enterococcus D366 and of the naturally glycopeptide-resistant species Lactobacillus casei, Pediococcus pentosaceus, Leuconostoc mesenteroides, and Enterococcus gallinarum
16. Peptidoglycan structure of Enterococcus faecium expressing vancomycin resistance of the VanB type
17. Outbreak of multidrug-resistant Enterococcus faecium with transferable vanB class vancomycin resistance
18. Epidemiologic analysis and genotypic characterization of a nosocomial outbreak of vancomycin-resistant enterococci
19. Effective treatment of multidrug-resistant enterococcal experimental endocarditis with combinations of cell wall-active agents
20. Effects of membrane-energy mutations and cations on streptomycin and gentamicin accumulation by bacteria: A model for entry of streptomycin and gentamicin in susceptible and resistant bacteria
21. High-level penicillin resistance among isolates of enterococci: Implications for treatment of enterococcal infections
22. Endocardites infectieuses de l'adulte. Propositions pour l'antibiotherapie curative
23. Triple-combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a moderately penicillin- and highly glycopeptide-resistant isolate of Enterococcus faecium
24. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium
25. Triple combination penicillin-vancomycin-gentamicin for experimental endocarditis caused by a highly penicillin- and glycopeptide-resistant isolate of Enterococcus faecium
26. Comparison of different beta-lactam-glycopeptide-gentamicin combinations for an experimental endocarditis caused by a highly beta-lactam-resistant and highly glycopeptide-resistant isolate of Enterococcus faecium
27. Absence of synergistic activity between ampicillin and vancomycin against highly vancomycin-resistant enterococci
28. Influence of high-level gentamicin resistance and beta-hemolysis on susceptibility of enterococci to the bactericidal activities of ampicillin and vancomycin
29. Emergence of increased resistance to quinupristin/dalfopristin during therapy for Enterococcus faecium bacteremia
30. Communique du Comite de l'Antibiogramme de la Societe Francaise de Microbiologie
31. Characterization of the chromosomal aac(6')-Ii gene specific for Enterococcus faecium
32. Resistance of enterococci to glycopeptides
33. Treatment of chronic bacterial prostatitis with temafloxacin
34. Enterococcal bacteremia in children: A review of seventy-five episodes in a pediatric hospital
35. Phenotypic identification of the genus Enterococcus and differentiation of phylogenetically distinct enterococcal species and species groups
36. Experimental bacterial endocarditis: I. Colonization of a sterile vegetation
37. Vancomycin-resistant Enterococcus faecium bacteremia: Risk factors for infection
38. Nosocomial bloodstream infections in United States hospitals: A three-year analysis
39. Increasing problems in the therapy of enterococcal infections
40. Vancomycin-resistant enterococci: Mechanism and clinical relevance
41. Therapy of enterococcal infections
42. Ribosomal resistance of clinical enterococcal to streptomycin isolates
43. Susceptibility of enterococci and Listeria monocytogenes to N-Formimidoyl thienamycin alone and in combination with an aminoglycoside
44. High-level resistance to gentamicin in clinical isolates of Streptococcus (Enterococcus) faecium
45. Identification of Enterococcus species isolated from human infections by a conventional test scheme
46. Influence of low-level resistance to vancomycin on efficacy of teicoplanin and vancomycin for treatment of experimental endocarditis due to Enterococcus faecium
47. Influence of inducible cross-resistance to macrolides, lincosamides, and streptogramin B-type antibiotics in Enterococcus faecium on activity of quinupristin-dalfopristin in vitro and in rabbits with experimental endocarditis
48. In vitro and in vivo activity of ciprofloxacin against enterococci isolated from patients with infective endocarditis
49. Nucleotide sequence analysis of the gene specifying the bifunctional 6'-aminoglycoside acetyltransferase 2'-aminoglycoside phosphotransferase enzyme in Streptococcus faecalis and identification and cloning of gene regions specifying the two activities
50. Antibacterial activity of quinupristin/dalfopristin: Rationale for clinical use
51. VanE, a new type of acquired glycopeptide resistance in Enterococcus faecalis BM4405
52. Overproduction of a low-affinity penicillin-binding protein and high-level ampicillin resistance in Enterococcus faecium
53. Identification of a streptococcal penicillin-binding protein that reacts very slowly with penicillin
54. Inconsistent bactericidal activity of triple-combination therapy with vancomycin, ampicillin, and gentamicin against vancomycin-resistant, highly ampicillin-resistant Enterococcus faecium
55. In vitro antimicrobial susceptibility of glycopeptide-resistant enterococci
56. Enterococci and vancomycin resistance
57. Therapy with RP 59500 (quinupristin/dalfopristin) for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns
58. Efficacy of ampicillin plus ceftriaxone in treatment of experimental endocarditis due to Enterococcus faecalis strains highly resistant to aminoglycosides
59. Nosocomial bacteremia due to Enterococcus faecalis without endocarditis
60. Failure of trimethoprim-sulfamethoxazole therapy in experimental enterococcal endocarditis
61. Constitutively vancomycin-resistant Enterococcus faecium resistant to synergistic beta-lactam combinations
62. Synergy and resistance to synergy between beta-lactam antibiotics and glycopeptides against glycopeptide-resistant strains of Enterococcus faecium
63. From foreign pharmacopoeias: 'New' antibiotics from old?
64. Enterococci and antifolate antibiotics
65. Nosocomial outbreak due to Enterococcus faecium highly resistant to vancomycin, penicillin, and gentamicin
66. In vivo development of teicoplanin resistance in a VanB Enterococcus faecium isolate
67. Continuous intravenous versus intermittent ampicillin therapy of experimental endocarditis caused by aminoglycoside-resistant enterococci
68. Treatment of experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin
69. Aztreonam
70. Critical importance of in vivo amoxicillin and cefotaxime concentrations for synergy in treatment of experimental Enterococcus faecalis endocarditis
71. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of DNA topoisomerase IV associated with quinolone resistance in Enterococcus faecalis
72. A cluster of vancomycin-resistant Enterococcus faecium in an intensive care unit
73. Comparative activity of quinupristin/dalfopristin and RPR 106972 and the effect of medium on in-vitro test results
74. VanA-mediated high-level glycopeptide resistance in Enterococcus faecium from animal husbandry
75. VRE: Animal reservoirs and food
76. Influence of VanE-type resistance on efficacy of vancomycin in vitro and in experimental endocarditis due to Enterococcus faecalis
77. Ampicillin plus ciprofloxacin therapy of experimental endocarditis caused by multidrug-resistant Enterococcus faecium
78. The role of chloramphenicol in the treatment of bloodstream infection due to vancomycin-resistant Enterococcus
79. Enterococci acquire new kinds of resistance
80. Bacterial resistance to macrolide, lincosamide and streptogramin antibiotics by target modification
81. Resistance of enterococci to aminoglycosides and glycopeptides
82. Two-step acquisition of resistance to the teicoplanin-gentamicin combination by VanB-type Enterococcus faecalis in vitro and in experimental endocarditis
83. Activity and diffusion of GAR-936 in experimental enterococcal endocarditis
84. Glycopeptide-resistant enterococci: Risk factors for colonization, morbidity and associated mortality
85. Differences in outcomes or patients with bacteremia due to vancomycin-resistant Enterococcus faecium or vancomycin-susceptible E. faecium
86. Effect of quinupristin/dalfopristin on the outcome of vancomycin-resistant Enterococcus faecium bacteraemia: Comparison with a control cohort
87. Hospital-acquired infection with vancomycin-resistant Enterococcus faecium transmitted by electronic thermometers
88. Synergic activity of vancomycin-quinupristin/dalfopristin combination against Enterococcus faecium
89. Successful treatment of meningitis due to multiply resistant Enterococcus faecium with a combination of intrathecal teicoplanin and intravenous antimicrobial agents
90. Treatment of CAPD-peritonitis due to glycopeptide-resistant Enterococcus faecium with quinupristin/dalfopristin
91. Synergistic effect of amoxicillin and cefotaxime against Enterococcus faecalis
92. Enterococcal bacteremia: Clinical features, the risk of endocarditis, and management
93. Enterococcal endocarditis: An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center
94. Transferable plasmids mediating multiple-antibiotic resistance in Streptococcus faecalis subsp. liquefaciens
95. Teicoplanin in the treatment of gram-positive-bacterial endocarditis
96. Treatment of endocarditis due to vancomycin-resistant Enterococcus faecium with quinupristin/dalfopristin, doxycycline, and rifampin: A synergistic drug combination
97. High-level resistance to gentamicin in clinical isolates of enterococci
98. In vitro activities of an investigational quinolone, glycylcycline, glycopeptide, streptogramin, and oxazolidinone tested alone and in combinations against vancomycin-resistant Enterococcus faecium
99. DNA fingerprinting of Enterococcus faecium by pulsed-field gel electrophoresis may be a useful epidemiologic tool
100. Emergence of Enterococcus as a significant pathogen
101. Enterococcus species, Streptococcus bovis and Leuconostoc
102. The enterococcus: A classic example of the impact of antimicrobial resistance on therapeutic options
103. Vancomycin-resistant enterococci
104. Successful treatment of vancomycin-resistant enterococcal infections with teicoplanin
105. Species-specific resistance to antimicrobial synergism in Streptococcus faecium and Streptococcus faecalis
106. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium
107. 14C-labeled streptomycin by enterococci
108. Therapeutic potential of rifampin in enterococcal infections
109. Enterococci resistant to multiple antimicrobial agents, including vancomycin: Establishment of endemicity in a university medical center
110. Treatment of infections caused by highly resistant enterococci
111. Beta-lactamase-producing enterococci
112. Enterococci
113. The life and times of the Enterococcus
114. Comparison of two beta-lactamase-producing strains of Streptococcus faecalis
115. Transferable beta-lactamase: A new mechanism for in vitro penicillin resistance in Streptococcus faecalis
116. Vancomycin-resistant Enterococcus faecium shunt infection in an infant: An antibiotic cure
117. Efficacy of vancomycin and teicoplanin alone and in combination with streptomycin in experimental low-level vancomycin-resistant, VanB-type Enterococcus faecalis endocarditis
118. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
119. Chloramphenicol for the treatment of vancomycin-resistant enterococcal infections
120. Enterococcus faecium and Enterococcus faecalis bacteremia: Acquisition and outcome
121. In vitro activities of linezolid against important gram-positive bacterial pathogens including vancomycin-resistant enterococci
122. Recovery of vancomycin-resistant enterococci on fingertips and environmental surfaces
123. Characterization and comparison of two penicillinase-producing strains of Streptococcus (Enterococcus) faecalis
124. Vancomycin-resistant Enterococcus faecium meningitis successfully treated with chloramphenicol
125. VanD-type glycopeptide-resistant Enterococcus faecium BM4339
126. Emergence of vancomycin resistance in the genus Streptococcus: Characterization of a vanB transferable determinant in Streptococcus bovis
127. Treatment of experimental endocarditis due to multidrug resistant Enterococcus faecium with ciprofloxacin and novobiocin
128. The vanB gene confers various levels of self-transferable resistance to vancomycin in enterococci
129. Identification of the satA gene encoding a streptogramin A acetyltransferase in Enterococcus faecium BM4145
130. Analysis of peptidoglycan precursors in vancomycin-resistant Enterococcus gallinarum BM4174
131. Rapid dissemination of beta-lactamase-producing, aminoglycoside-resistant Enterococcus faecalis among patients and staff on an infant-toddler surgical ward
132. Genetic basis of tetracycline resistance in urogenital bacteria
133. Vancomycin-resistant Enterococcus faecium in hospitalized children
134. Penicillin-binding protein 5 sequence alterations in clinical isolates of Enterococcus faecium with different levels of beta-lactam resistance
135. Activity of intravenous LY333328 alone or combined with gentamicin in vitro and in experimental endocarditis due to Enterococcus faecalis
136. Activity and diffusion of LY333328 in experimental endocarditis due to vancomycin-resistant Enterococcus faecalis
137. Major trends in the microbial etiology of nosocomial infection
138. Transfer of Streptococcus faecalis and Streptococcus faecium to the genus Enterococcus nom. rev. as Enterococcus faecalis comb. nov. and Enterococcus faecium comb. nov.
139. Efficacy of teicoplanin for enterococcal infections: 63 Cases and review
140. Antimicrobial susceptibility patterns of enterococci causing infections in Europe
141. In vitro activity of LY333328, an investigational glycopeptide antibiotic, against enterococci and staphylococci
142. A case-control study of nosocomial ampicillin-resistant enterococcal infection and colonization at a university hospital
143. Mechanism of action of oxazolidinones: Effects of linezolid and eperezolid on translation reactions
144. Synergistic killing of vancomycin-resistant enterococci of classes A, B, and C by combinations of vancomycin, penicillin, and gentamicin
145. Enterococcal meningitis: Report of four cases and review
146. Risk factors for mortality associated with enterococcal bloodstream infections
147. Dissemination of vancomycin-resistant enterococci in the United States
148. Continuous-infusion ampicillin therapy of enterococcal endocarditis in rats
149. Sur un diplocoque saprophyte de l'intestin susceptible de devenir pathogene
150. Susceptibilities of enterococci to twelve antibiotics
151. High-level penicillin resistance and penicillin-gentamicin synergy in Enterococcus faecium
152. In vitro activity of the new ketolide HMR3647 in comparison with those of macrolides and pristinamycins against Enterococcus spp.
153. Influence of oral glycopeptides on the fecal flora of human volunteers: Selection of highly glycopeptide-resistant enterococci
154. Endocarditis caused by an Enterococcus faecalis high-level resistant to aminoglycosides: Failure of ampicillin and ceftriaxone combined therapy
155. Teicoplanin in the treatment of enterococcal endocarditis: Clinical and microbiological study
156. Rapid increase in the prevalence of high-level aminoglycoside resistance among enterococci isolated from blood cultures during 1989-1991
157. Antibiotic treatment of experimental endocarditis due to vancomycin- and ampiciliin-resistant Enterococcus faecium
158. One or two low affinity penicillin-binding proteins may be responsible for the range of susceptibility of Enterococcus faecium to benzylpenicillin
159. Treatment of endocarditis with teicoplanin: A retrospective analysis of 104 cases
160. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms
161. Treatment of streptomycin-susceptible and streptomycin-resistant enterococcal endocarditis
162. Efficacy of teicoplanin in two dosage regimens for experimental endocarditis caused by a beta-lactamase-producing strain of Enterococcus faecalis with high-level resistance to gentamicin
163. Case of vancomycin-resistant Enterococcus faecium infection associated with a transjugular intrahepatic portosystemic shunt that was treated with Quinupristin/Dalfopristin after bacteremia persisted with alatrofloxacin therapy
164. Synergy of an investigational glycopeptide, LY333328, with once-daily gentamicin against vancomycin-resistant Enterococcus faecium in a multiple-dose, in vitro pharmacodynamic model
165. Structure of the low-affinity penicillin-binding protein 5 PBP5fm in wild-type and highly penicillin-resistant strains of Enterococcus faecium